Introduction {#Sec1}
============

Lower respiratory tract infections (LRTI) are a leading cause of morbidity and mortality worldwide \[[@CR1]\]. As guided by clinical and epidemiological factors, microbiological investigations may be carried out to determine the etiology, especially for community-acquired pneumonia (CAP) with moderate and high severity \[[@CR2], [@CR3]\]. Nevertheless, CAP pathogens are diversified which render etiologic diagnosis challenging. The mainstay microbial culture is time-consuming and may only identify a pathogen up to 40% of cases due to variable growth requirements \[[@CR4]\]. Multiplex polymerase chain reaction (PCR) assays have been demonstrated useful for improving pathogen detection from lower respiratory specimens \[[@CR5], [@CR6]\], yet the targets are confined to key bacteria which may only represent the tip of an iceberg.

Recently, next-generation sequencing (NGS) facilitates a universal approach for pathogen detection, which may revolutionize infectious disease diagnostics \[[@CR7]\]. In particular, Nanopore technology provides the speed that can shorten sample-to-answer time, which is important for the severely ill. From literature, several research groups explored the use of Nanopore sequencing for pneumonia diagnosis, utilizing both metagenomic and targeted approaches \[[@CR8]--[@CR11]\]. In this study, we adopted the targeted approach because it enables higher depth of microbial reads and thus allowing more room for multiplexing which significantly lowers the cost. We developed a targeted Nanopore method for simultaneous detection of bacterial and fungal pathogens, and compared its performance with routine infectious disease workups on archived respiratory specimens harboring diversified microbial species.

Methods {#Sec2}
=======

Specimens {#Sec3}
---------

The specimens were selected based on microbial diversity. The 43 respiratory specimens were collected between May 2016 and September 2019 in Department of Pathology, Hong Kong Sanatorium & Hospital. These comprised 34 lower and 9 upper respiratory specimens, and the details are summarized in Table [1](#Tab1){ref-type="table"}. Table 1Details of clinical specimens and results of Nanopore sequencingPatientSpecimenRoutine infectious disease workupsNanopore sequencingPossible pathogens^\#^ (abundance)RemarksN^\*^TestResult^§^Time^†^Abundance^¶^1BAL5Culture*C. albicansC. glabrata*4 min4 min61%22%//2Sputum2Culture*Candida* sp.^(M)^4 min61%**/**/3Sputum6Culture*S. pyogenes*^(H)^9 min59%//4Sputum5Culture*H. influenzae*^(H)^22 min41%//5BAL7CultureMicroscopy*C. albicans*^(M)^*P. jirovecii*5 min5 min93%0.1%//6Sputum5Culture*S. pneumoniae*^(H)^5 min6%/*S. pneumoniae* antigen (urine): negative7BAL7CulturePCR*C. albicans*^(S)^*L. pneumophila*5 min4 min98%98%//8BAL7Culture*C. albicans*^(S)^2 min85%//9NPS1PCR*B. parapertussis*32 min0.2%//10Sputum3Culture*M. abscessus*27 min0.3%**/**AFB smear: negative11BAL5Culture*M. avium* complex*Raoultella* sp.^(S)^*S. aureus*^(S)^NDND2 minNDND0.5%/AFB smear: negative12NPS2PCRSerum IgG*C. pneumoniae*2 min0.8%***S. pneumoniae*(80%)Bacterial culture: not performedConsensus sequence showed 100% identity to*S. pneumoniae***13Sputum3PCR*M. pneumoniae*10 min99%//14NPA3Culture*C. pseudodiphtheriticum*^(H)^4 min4%//15NPS2Culture*M. catarrhalis*^(M)^16 min98%//16Sputum2Culture*M. catarrhalis*^(M)^13 min98%//17Lung Bx5Culture*C. neoformans*3 min67%//18Sputum4PCR*P. jirovecii*12 min97%***L. pneumophila*(11%)*L. pneumophila*PCR: not performedConsensus sequence showed 99% identity to*L. pneumophila****P. jirovecii* DNA: 3.13 × 10^6^ copies/mL19Sputum6PCRCultureCulture*P. jiroveciiS. aureus*^(S)^*C. albicans*^(S)^8 min43 min8 min0.001%0.1%74%/*P. jirovecii* DNA: 1.77 × 10^6^ copies/mL20NPS2PCR*C. pneumoniae*1 min0.03%//21BAL2NGS*R. mucilaginosa*1 min67%**/Culture-negative*R. mucilaginosa*Shotgun NGS by MiSeqConsensus sequence showed 99% identity to*R. mucilaginosa***22BW5PCRCulture*M. tuberculosis* complex*C. dubliniensis*9 min3 min0.01%2%**/**AFB smear: positive23NPS1PCR*B. pertussis*40 min0.02%//24BAL7CultureCulturePCR*C. albicansP. kudriavzeviiP. jirovecii*1 minND1 min31%ND33%***L. wadei*(64%)Culture-negative*L. wadei*Consensus sequence showed 99% identity to*L. wadei****P. jirovecii* DNA: 3.43 × 10^7^ copies/mL25ETA4Culture*Candida* sp.^(S)^NDND//26BAL4PCR*P. jirovecii*2 min50%**/***P. jirovecii* DNA: 8.82 × 10^4^ copies/mL27TA2Culture*C. dubliniensis*^(S)^1 min90%**/**/28NPS2PCRSerum IgM*C. pneumoniae*1 min84%//29BW3Culture*S. maltophilia*^(S)^*C. albicans*^(S)^*C. glabrata*^(S)^1 min1 min1 min7%51%37%//30Sputum6PCR*M. pneumoniae*1 min65%//31Sputum7PCR*M. pneumoniae*1 min53%//32BAL6PCR*M. pneumoniaeC. albicans*2 minND1%ND/Fungus culture: negative33Sputum5PCR*M. pneumoniae*1 min90%//34BAL7Culture*C. albicans*^(S)^2 min86%/Serum beta-D-glucan: negative35Sputum6Culture*Burkholderia* sp.^(M)^1 min46%//36Sputum5PCR*M. pneumoniae*1 min12%//37Sputum7CultureUrine Ag*S. pneumoniae*^(M)^3 min0.6%***C. albicans*(85%)Fungus culture: not performedConsensus sequence showed 100% identity to*C. albicans***38Sputum2PCR*P. jirovecii*NDND***C. striatum*(84%)*C. haemulonis*(70%)***P. jirovecii* DNA: \< 760 copies/mL**Bacterial/ fungus culture: not performedConsensus sequence showed 99 and 100% identity to*C. striatum*and*C. haemulonis*, respectively.**39Sputum2PCR*M. pneumoniae*1 min47%//40NPS1PCR*M. pneumoniae*NDND/PCR Cp value = 37.06 (45 cycles)41NPS1PCR*M. pneumoniae*2 min0.9%//42Sputum1CultureNormal flora22 min//16S data revealed reads from normal flora dominated by *N. perflava* (19.55%) with *H. influenzae* colonization (1.68%).ITS sequencing: not performed43Sputum6CultureNormal flora87 min//16S data revealed reads from normal flora dominated by *L. buccalis* (46.08%).ITS data revealed no fungal reads.Fungus culture: negativeSummary○ Average number of routine tests taken for bacterial/ fungal etiology: 4 (1--7)○Average elapsed sequencing time of the first target read: 7 min (1--43 min; pre-sequencing preparation: 5 h)○ Concordance with routine test results: 47/54 = 87.04%○ Possible pathogens detected by Nanopore workflow: 7 from 6 patients^\*^Number of tests taken for bacterial/ fungal etiology^§^Scanty^(S)^, moderate^(M)^ and heavy^(H)^ growth correspond to microbial growth up to primary, second and third sector of culture agar plate, respectively^†^Elapsed Nanopore sequencing time of first target reads^¶^Bacterial and fungal abundance were calculated separately^\#^Possible pathogens not detected by routine workups but identified by Nanopore sequencing

Deoxyribonucleic acid (DNA) extraction and PCR {#Sec4}
----------------------------------------------

Standard laboratory practices were applied to minimize risk of infection and contamination. DNA extraction was performed using EMAG (bioMérieux, Marcy, I'Etoile, France) with blank lysis buffer as negative control. Bacterial 16S ribosomal ribonucleic acid (rRNA) gene and fungal internal transcribed spacer (ITS) region were amplified using universal primers 27F-1492R/ 533F-1100R and ITS5-ITS4, respectively, with human beta-globin gene as PCR inhibition control. Primer sequences and PCR conditions are described in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. Table 2PCR primers for bacterial 16S, fungal ITS and human beta-globin PCRPrimersSequences (5′ to 3′)References16S (27F)AGAGTTTGATCMTGGCTCAG\[[@CR12]\]16S (533F)GTGCCAGCMGCCGCGGTAA\[[@CR13]\]16S (1100R)AGGGTTGCGCTCGTTG\[[@CR14]\]16S (1492R)TACGGYTACCTTGTTACGACTT\[[@CR12]\]ITS5GGAAGTAAAAGTCGTAACAAGG\[[@CR15]\]ITS4TCCTCCGCTTATTGATATGCHuman beta-globin forward (BG-F)GAAGAGCCAAGGACAGGTAC\[[@CR16]\]Human beta-globin reverse (BG-R)GGAAAATAGACCAATAGGCAGTable 3Master mix constituents and PCR conditions16S PCR***Master mix preparation (for single reaction)*ReagentVolume/μL**Platinum PCR SuperMix High Fidelity (Invitrogen)2027F/ 533F (10 μM)11492R/ 1100R (10 μM)1DNA5***PCR conditions*Temperature/**^**o**^**CTimeNo. of cycles**942 min194556830 s30 s2 min30687 min112Hold/ITS/ human beta-globin PCR***Master mix preparation (for single reaction)*ReagentVolume/μL**10X PCR Buffer II (Applied Biosystems)2.525 mM MgCl~2~ (Applied Biosystems)1.5AmpliTaq Gold DNA Polymerase (Applied Biosystems)0.510 mM dNTPs (Roche)0.5Molecular grade water (Sigma)10ITS5/ BG-F (10 μM)2.5ITS4/ BG-R (10 μM)2.5DNA5***PCR conditions*Temperature/**^**o**^**CTimeNo. of cycles**9510 min19515 s5230 s507290 s727112Hold/

Nanopore sequencing library preparation {#Sec5}
---------------------------------------

Nanopore sequencing libraries were prepared using Ligation Sequencing Kit 1D (SQK-LSK109) (Oxford Nanopore Technologies, Oxford, England) with or without PCR-free Native Barcoding Expansion Kit (EXP-NBD104/114) (Oxford Nanopore Technologies, Oxford, England). The libraries were loaded and sequenced on MinION flow cells (FLO-MIN106D R9.4.1) (Oxford Nanopore Technologies, Oxford, England) after quality control runs.

Data analysis {#Sec6}
-------------

MinKNOW version 2.0 was used for live basecalling. FASTQ files were analyzed on Nanopore EPI2ME platform with default minimum qscore of 7. Bacterial and fungal identification were facilitated via 16S and 'What's in my Pot?' (WIMP) workflows, respectively. Reads assigned to all target and possible pathogens were counter-checked with National Center for Biotechnology Information (NCBI) basic local alignment search tool (BLAST), or re-analyzed by GAIA 2.0. For all possible pathogens, consensus sequences were built from BAM files using Unipro UGENE (version 1.29.0) and their similarity to reference genomes was determined. The elapsed sequencing time of first target reads was recorded. Relative abundance values of bacterial and fungal pathogens were calculated separately.

Confirmation of possible pathogens {#Sec7}
----------------------------------

Presence of possible pathogens was further confirmed by PCR-sequencing using genus- or species-specific primers (Table [4](#Tab4){ref-type="table"}). Table 4Genus- and species-specific primers for confirmation of possible pathogensPrimersSequences (5′ to 3′)References*S. pneumoniae* forwardAGGATAAGGAACTGCGThis study*S. pneumoniae* reverseCTTATTTTCTGACCTTTCA*L. wadei* forwardCCAAGCCAACCTTCAAAGCCThis study*L. wadei* reverseACCTTGTTACGACTTCACCCC*C. albicans* forwardCTGCTGATATTACTGTTGGTTC\[[@CR17]\]*C. albicans* reverseCCACCAATACCAACGGTATC*Corynebacterium* forwardCACTGTGAGGTGGAGCGAATThis study*Corynebacterium* reverseCCACCTTCGACAGCTCCCTA*C. haemulonis* forwardCGCATCGATGAAGAACGCAGThis study*C. haemulonis* reverseAGCGTAGACTTCACTGTGGC

Results {#Sec8}
=======

The results are summarized in Table [1](#Tab1){ref-type="table"}. The first target reads were detected with average sequencing time of 7 min (1--43 min), plus 5 h of pre-sequencing preparation. Nanopore successfully identified majority of the microbes (47/54, 87.04%), and the false negatives were primarily due to low microbial burden, as reflected by negative smear (Patient 11), scanty or no microbial growth from culture (Patient 11, 25 and 32), and late cycle threshold values of real-time PCR assays (Patient 38 and 40).

Interestingly, Nanopore identified 7 possible pathogens from 6 patients, which were not detected by routine workups. The consensus sequences of these possible pathogens showed 99--100% identity to reference sequences, and their presence was confirmed by PCR-sequencing except for Patient 18 due to sample insufficiency. The 7 possible pathogens included common causes of typical and atypical pneumonia (*n* = 2: *Legionella pneumophila* and *Streptococcus pneumoniae*), as well as opportunistic pathogens (*n* = 5: *Candida albicans, Candida haemulonis, Corynebacterium striatum*, *Leptotrichia wadei* and *Rothia mucilaginosa*). These findings might be attributable to 2 factors. First, the routine workups did not include tests for microbes concerned (n = 5). Taking Patient 12 as an example, results of sputum PCR and serum immunoglobulin G test suggested *Chlamydia pneumoniae* infection, yet 80 and 0.8% of 16S reads were mapped to *S. pneumoniae* and *C. pneumoniae*, respectively. The former was more abundant and might have been isolated by culture, however, bacterial culture was not included in the workup. Another factor was negative culture (*n* = 2). For instance, in the bronchoalveolar lavage of Patient 24, majority of 16S reads (64%) were mapped to *L. wadei*, which might prefer anaerobic growth conditions and therefore not isolated from standard culture \[[@CR18]\].

Discussion {#Sec9}
==========

Our data revealed the heterogeneous nature of respiratory microbiome of the patients, which is hardly hinted by clinical signs and symptoms \[[@CR19]\], but the content of microbiological investigation is often determined by this limited information. Considering the 6 patients with possible pathogens, half of the routine workups comprised 4--7 tests (average for all patients: 4). To a certain extent, the data revealed the bottleneck of etiologic diagnosis, that is, routine workups comprised a bundle of narrow-spectrum tests without targeting the culprit. Broad-spectrum, hypothesis-free NGS methods may contribute to improved etiologic diagnosis by supplementing the limitations of conventional tests and providing hints for further microbiological follow-up. A more complete picture on relative abundance of each microbial species may also help distinguish between causative agents and colonizers, especially in co-infection. Benefiting from the real-time sequencing by Nanopore technology, sample-to-answer time may be reduced to facilitate prompt pathogen-specific confirmatory work and treatment, which are essential for improved clinical outcome.

There are several diagnostic-grade molecular tests for pneumonia diagnosis, for example, the U.S. Food and Drug Administration (FDA)-approved BioFire FilmArray Pneumonia Panel and Explify Respiratory by ARUP Laboratories and IDbyDNA. The former identifies 33 targets from lower respiratory specimens in about 1 h, including 18 common LRTI bacteria with semi-quantitative results for 15 \[[@CR20]\]. The latter works by metagenomic DNA and RNA sequencing (illumina NextSeq) enabling non-targeted detection of virtually any microbial targets within 48 h \[[@CR21]\]. Our targeted Nanopore method is an intermediate between the two, in terms of speed (FilmArray \> Nanopore \> Explify) and detection spectrum (Explify \> Nanopore \> FilmArray). FilmArray appears to be a good option for first-line pathogen detection and Explify/ Nanopore may be a useful investigatory tool for culture- and FilmArray-negative opportunistic infections caused by rare pathogens. Considering the reagent cost, our Nanopore method is a competitive option among the 3. The per-sample reagent cost was about USD 68.87 for a 24-plex MinION run, and could be flexibly scaled for single sporadic cases on Flongle (USD 218.23) (Table [5](#Tab5){ref-type="table"}). Nevertheless, as Nanopore technology is rapidly evolving, it is not easy to clinically validate a Nanopore-based assay at this moment due to requirements on 'wet lab' and bioinformatics analysis method standardization. Table 5Estimated reagent cost of Nanopore workflow (24-plex for MinION; 1 specimen for Flongle)Reagent cost/ service charge per specimen (USD)**NanoporeSend-out forpneumonia testingFDA-cleared pneumonia panel(33 targets)MinION(23 specimens + 1 NC)Flongle(1 specimen + 1 NC)DNA extraction**13.4425.76//**PCR**2.043.91//**Library preparation& sequencing**53.39188.56//**Total68.87218.23514.84321.77**

Our method had several limitations. First, the sensitivity for low-abundance microbial species was lower in a background of upper respiratory commensals. Second, we observed that 27F primer failed to detect *C. pneumoniae* for Patient 12, 20 and 28. In silico sequence evaluation revealed mismatches at 3′ end of 27F primer when aligned with *C. pneumoniae* reference sequence (nucleotide 8--20, NCBI Accession Number: NR_026527.1). The problem was resolved by including 533F-1100R primers for 16S analysis and this highlighted the importance of optimal primer choices for the best species coverage. We also observed that several species were misidentified by EPI2ME, for instance, *Streptococcus mitis* was misidentified as *S. pneumoniae*, and *C. albicans* was misidentified as *Candida auris*. Confirmation of results with alternative pipelines is therefore advisable. Like many DNA-based molecular assays, we could not determine cell viability from sequencing data. Close communication between physicians and laboratorians is therefore warranted to correlate laboratory data with clinical presentation. In addition, as this was purely a laboratory microbiology study, we had no clinical outcome data on treatment results to validate the etiology of each case.

Conclusion {#Sec10}
==========

Our data shed light on potential value of targeted Nanopore sequencing for supplementing the limitations of conventional diagnostic workflow. It may not have the best of its value for common non-viral causes of respiratory infection, as these can be readily resolved by microbial culture and multiplex PCR, yet it may contribute to improved etiological diagnosis of opportunistic infection caused by rare pathogens. Future prospective study with greater pathogen diversity and clinical outcome data is warranted to further assess assay performance and streamline the protocol. With continuously improving sequencing technology as well as user-friendly workflow and price, we envision that Nanopore-based methods will be closer to the doors of clinical laboratories in the near future.

BLAST

:   Basic local alignment search tool

CAP

:   Community-acquired pneumonia

DNA

:   Deoxyribonucleic acid

FDA

:   Food and drug administration

ITS

:   Internal transcribed spacer

LRTI

:   Lower respiratory tract infection

NCBI

:   National center for biotechnology information

NGS

:   Next-generation sequencing

PCR

:   Polymerase chain reaction

rRNA

:   Ribosomal ribonucleic acid

WIMP

:   'What's in my Pot?'

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

We thank the colleagues of Department of Pathology, Hong Kong Sanatorium & Hospital, for their dedicated and professional work on routine laboratory diagnosis.

BSFT and WSC conceived and designed the study. BSFT, ESKM, TLC, CHA, SML, DNH, EYLW, MYT, MKN and WSC were involved in data collection and analysis. WSC wrote the first draft. All authors critically reviewed and approved this manuscript.

Not applicable.

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

This study was conducted with the approval of Research Ethics Committee (REC) of Hong Kong Sanatorium & Hospital. The reference number is RC-2019-29. The specimens used were left-over total nucleic acid after routine testing. All personal identifiers were removed in the whole research process. Consent to participate: not applicable.

Not applicable.

The authors declare that they have no competing interests.
